The Impact of SARS-CoV-2 Transmission Fear and the COVID-19 Pandemic on the Mental Health of Patients with Primary Immunodeficiency Disorders and Severe Asthma, and Other High-Risk Groups

Çölkesen, Fatih; Kılınçel, Oğuzhan; Sözen, Mehmet; Yıldız, Eray; Beyaz, Şengül; Çölkesen, Fatma; Aytekin, Gökhan; Koçak, Mehmet; Alsancak, Yakup; Araz, Murat; Arslan, Şevket

doi:10.21911/aai.651

Cited by 7 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the general population, patients with asthma have a higher prevalence of anxiety and depression. With the COVID-19 pandemic, there is potential threat to exacerbate an existing mood disorder or cause a new one, therefore, affecting effective control of asthma [46].…”

Section: Diagnostic and Assessment Strategies Of Asthma During Corona...mentioning

confidence: 99%

Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps

Assaf

Tarasevych

Diamant

et al. 2020

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewAlthough respiratory viruses are common triggers of asthma exacerbation, it is unknown whether this also applies to infection with SARS-CoV-2. Indeed, patients with asthma and allergy appear underrepresented in large reports of COVID-19 cases worldwide. In this review, we evaluate existing literature on this topic and potential underlying mechanisms for any interrelationship between asthma and COVID-19. Recent findingsData from several preclinical and clinical reports suggest a lower susceptibility for COVID-19 in patients with underlying type 2 airway inflammation including asthma that may be related to a reduced expression of ACE2 and TMPRSS2 receptors for SARS-CoV-2. Corticosteroids further decrease expression of the ACE2 and TMPRSS2 receptors, hence may also have a protective effect against infection with SARS-CoV-2. In addition, some studies suggest that the reported improvement in asthma control and a reduction in asthma exacerbations during the COVID-19 pandemic may be related to improvement in adherence to controller therapy and reduced exposure to triggers, such as other respiratory viruses and air pollutants. Recent data point towards differential susceptibility for COVID-19 among asthma patients based on their phenotype and/or endotype. On the basis of existing evidence, continuation with controller therapies is recommended for all patients with asthma. For patients with severe uncontrolled asthma infected by SARS-CoV-2, adjustment of controllers and biologics should be based on a multidisciplinary decision.

show abstract

Section: Diagnostic and Assessment Strategies Of Asthma During Corona...mentioning

confidence: 99%

Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps

Assaf

Tarasevych

Diamant

et al. 2020

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…The four fears scales were all found to significantly predict symptoms of depression and post-traumatic stress ( Cottin et al, 2021 ). The Turkish translation of the FIVE adult-version was tested in its original hypothesized factor structure and found to strongly correlate with symptoms of anxiety (r = 0.83) and moderately correlate with depressive symptoms (r = 0.66) ( Çölkesen, Kilincel, & Sozen, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Fear of illness & virus evaluation (FIVE) COVID-19 scales for children-parent/caregiver-report development and validation

Sáez-Clarke¹,

Comer²,

Evans³

et al. 2022

Journal of Anxiety Disorders

View full text Add to dashboard Cite

“…In terms of the outcome of viral infections, patients with asthma were found to have a worse trend during the previous epidemics by coronaviruses [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy

Nicola

Borrelli

Ridolfi

et al. 2022

JPM

View full text Add to dashboard Cite

Introduction: Asthma, along with inhaled steroids, was initially considered a risk factor for worse clinical outcomes in COVID-19. This was related to the higher morbidity observed in asthma patients during previous viral outbreaks. This retrospective study aimed at evaluating the prevalence of asthma among patients admitted due to SARS-CoV-2 infection as well as the impact of inhaled therapies on their outcomes. Furthermore, a comparison between patients with asthma, COPD and the general population was made. Methods: All COVID-19 inpatients were recruited between February and July 2020 from four large hospitals in Northwest Italy. Data concerning medical history, the Charlson Comorbidity Index (CCI) and the hospital stay, including length, drugs and COVID-19 complications (respiratory failure, lung involvement, and the need for respiratory support) were collected, as well as the type of discharge. Results: patients with asthma required high-flow oxygen therapy (33.3 vs. 14.3%, p = 0.001) and invasive mechanical ventilation (17.9 vs. 9.5%, p = 0.048) more frequently when compared to the general population, but no other difference was observed. Moreover, asthma patients were generally younger than patients with COPD (59.2 vs. 76.8 years, p < 0.001), they showed both a lower mortality rate (15.4 vs. 39.4%, p < 0.001) and a lower CCI (3.4 vs. 6.2, p < 0.001). Patients with asthma in regular therapy with ICS at home had significantly shorter hospital stay compared to those with no treatments (25.2 vs. 11.3 days, p = 0.024). Discussion: Our study showed that asthma is not associated with worse outcomes of COVID-19, despite the higher need for respiratory support compared with the general population, while the use of ICS allowed for a shorter hospital stay. In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, according to their multiple comorbidities.

show abstract

The Impact of SARS-CoV-2 Transmission Fear and the COVID-19 Pandemic on the Mental Health of Patients with Primary Immunodeficiency Disorders and Severe Asthma, and Other High-Risk Groups

Cited by 7 publications

References 31 publications

Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps

Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps

Fear of illness & virus evaluation (FIVE) COVID-19 scales for children-parent/caregiver-report development and validation

COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy

Contact Info

Product

Resources

About